controversies in prostate diseases
DESCRIPTION
Controversies in Prostate Diseases. Europa Uomo Masterclass L. Denis Krakow, February 6, 2009. Understanding Prostate Diseases. Prostate Cancer is a chronic Disease. Purpose of this Chat Session. Highlight the uncertainty in prostate diseases. 2.Address overdetection / overtreatment. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/1.jpg)
Controversies in
Prostate DiseasesEuropa Uomo Masterclass
L. DenisKrakow, February 6, 2009
![Page 2: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/2.jpg)
Understanding Prostate Diseases
Prostate Cancer is a chronic Disease
![Page 3: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/3.jpg)
Purpose of this Chat Session
1. Highlight the uncertainty in prostate diseases.
2. Address overdetection / overtreatment.
3. Address undertreatment
OCA 2009
![Page 4: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/4.jpg)
Europa Uomo Strategy and Aims
1. Protect the patient with focus on quality of life & solidarity.
2. Inform and educate evidence based care and values our business.
3. Collaborate and understand optimal medical care.
OCA 2009
![Page 5: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/5.jpg)
The Way Forward
1. Individual prevention and treatment according to optimal treatment and care.
2. Reduce over- and undertreatment.
OCA 2009
![Page 6: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/6.jpg)
The lost patient
Tsunami information (Professionals, media, friends)
The medical labyrinth
EBM GuidelinesNomograms
Loss of personality
Outcome resultsStatistics
PANIC
OCA 2009
![Page 7: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/7.jpg)
Request of a Patient
• Professional expertise specialist
• Expertise and guidance general practitioner
• Support from his environment
Cure or ControlQuality of Life
We want our place in Society
OCA 2009
![Page 8: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/8.jpg)
Uncertainties Prostate Cancer
• Early prostate cancer has no symptoms
• DRE not much help
• PSA non specific, variable
• Imaging TRUS, MRI not perfect
• Biopsy techniques / pathology reports
• Treatment choice
We need: - Marker for Progression
- % of trifectaOCA 2009
![Page 9: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/9.jpg)
Uncertainty with the Doctor
1. Limits of knowledge & training
2. Feels secure in his own specialty
3. Never enough time to communicate with the patient
OCA 2009
![Page 10: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/10.jpg)
Localized Prostate Cancer
Preferred RXAll
Replies (%)
U.S. Physicians
R.O. (%)
Urol. (%)
M.O. (%)
Radiotherapy 40 92 8 46
Prostatectomy 40 8 80 42
Other RX 20 0 12 12
![Page 11: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/11.jpg)
Do we have time for a secure diagnosis / find rest with the idea.
1. PCa begins at age 30, present in half of men age 50 and increasing with age.
2. These cancers need 20 year (38 doublings) to be detected.
3. From diagnosis to death 15 years. With PSA 5 year survival obsolete.
OCA 2009
![Page 12: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/12.jpg)
Relativity of Prostate Cancer in Belgium KCE (knowledge)
Of 100 Belgian men before 75 years of age
- 64 have latent cancer
- 2 to 6 are diagnosed
- 1 died of PCA
OCA 2009
![Page 13: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/13.jpg)
Overdetection is a fact
Men PCa Women Bra
Inc. Mortality Inc. Mortality
2004 202,1 68,2 275,1 88,4
2006 301,5 67,8 319,985,3
Europa 25 * thousands, IARC
Incidence en Mortality 2004 - 2006
![Page 14: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/14.jpg)
PSA ng/ml Number of men
Number (%) with prostate cancer
Number (% of cancer) withhigh-grade prostate cancer
< 0.5 486 32 (6.6) 4 (12.5)0.6 – 1.0 791 80 (10.1) 8 (10.0)1.1 – 2.0 998 170 (17.0) 20 (11.8)2.1 – 3.0 482 115 (23.9) 22 (19.1)3.1 – 4.0 193 52 (26.9) 13 (25.0)Total 2950 449 (15.2) 67 (14.9)
Indolent Cancer is a FactPCa and HGca (>7 Gleason) by PSA level (>4 ng/ml) in the Prostate Cancer Prevention Trial study.
![Page 15: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/15.jpg)
Bowery Series: Arbitrary Open BiopsyAge, frequency, and diagnosis of prostatic disease in
300 patients
Age BPH Ca % Ca
30 – 39 2 --- ---
40 – 49 46 2 4.2
50 – 59 116 17 12.9
60 – 69 82 17 16.1
70 – 79 14 3 16.9
80 – 89 1 --- ---
Total: 261 39
P. Hudson, Cancer 1954
![Page 16: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/16.jpg)
![Page 17: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/17.jpg)
Primary Treatment according to Specialist Consult (N-85.088)
Specialty RP % XRT % Hormones % A.S.
Urology (N = 42,309)65-69 (N = 12,248) 70 5 7 18
70-74 (N = 10,751) 40 8 17 31
75+ (N = 19,310) 5 4 45 46
Urology / Medical Oncology (N = 2,329)65-69 (N = 601) 53 17 14 16
70-74 (N = 657) 38 22 17 23
75+ (N = 1,071) 5 15 46 34
T. Jang, NCI, 2007
![Page 18: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/18.jpg)
Primary Treatment according to Specialist Consult (N-85.088)
Specialty RP % XRT % Hormones % A.S.
Urology / Radiation Oncology (N = 37,540)65-69 (N = 10,604) 15 78 3 470-74 (N = 14,058) 7 85 4 475+ (N = 12,878) 2 85 7 6
Urology, Radiation & Medical Oncology (N = 2,910)65-69 (N = 890) 19 70 6 570-74 (N = 1,037) 8 80 7 5
75+ (N = 983) 2 79 12 7
T. Jang, NCI, 2007
![Page 19: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/19.jpg)
Active Surveillance vs. Watchful Waiting
Fit Patient Co-Morbidity
Low risk Cancer High risk Cancer
PSA dynamics define treatment
(+ biopsies)
Symptoms define treatment
Option: Cure Option: PalliationOCA, 2008
![Page 20: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/20.jpg)
Mismatch
• Organ dysfunction increases toxicity / side-effects
• Out of 438 patients, 389 (89%) with known dysfunction.
• More than 1/3 received inappropriate treatment
• Communication problems ?
Chen 2008
![Page 21: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/21.jpg)
New Technology
1. Not the necessity but availability defines frequent use.
2. Good treatment not supported by industry fails.
3. Replacement ‘old’ treatments by new ones.
4. The learning curve of technology.
W. Oosterlinck 2008
![Page 22: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/22.jpg)
Choice of Curative Treatment
1. Surgery: Anatomic Prostatectomy in T1, T2 and T3 cases
2. Radiatation: EBRT / Brachytherapy
in T1, T2 well and intermediate risk
in T3 combination hormones
3. Active Surveillance
OCA 2009
![Page 23: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/23.jpg)
Avoid Undertreatment
1. Treatment decision based on SIOG evaluation
2. Salvage treatment after RP (ECE, rising PSA) EBRT or reverse
3. A double negation in watchful waiting (no symptoms, less than calculated life expectancy)
OCA 2009
![Page 24: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/24.jpg)
Castration Resistant Prostate Cancer
1. About 20% of diagnosed, advanced PCa has diminished lowering PSA below 4 ng/ml
2. After secondary hormonal treatment:
AA withdrawal – DES – MAB – Abiraterone seen as resistant
3. Docetaxel & combinations first choice
4. Experimental: Immunotherapy, growth factors, gen therapy
5. Lifestyle in all casesOCA 2009
![Page 25: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/25.jpg)
Close Communication Problems
Knowledge Reality
Prevention Treatment
Rich Poor
Collaboration Olympic stand
Transparant ObscureOCA, 2009
![Page 26: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/26.jpg)
Life Expectancy
• Age
• Health
• Activity
• Address
• Social Status
OCA 2009
![Page 27: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/27.jpg)
Partnerships Europa Uomo
EPPOSI OECI ESU ESOP – ESMO
EAU – EONS – ECCO
ECPC Eurocan+Plus Europa Donna PROCABIO
WWPCC TRANSMARK
Europa Uomo - ESO
Europa Uomo 2009
![Page 28: Controversies in Prostate Diseases](https://reader031.vdocuments.site/reader031/viewer/2022012919/5681554f550346895dc31b4a/html5/thumbnails/28.jpg)
Thank you for not sleeping.
Don’t shoot the pianist.
OCA, 2009